CStone Pharmaceuticals Reveals Strategic Growth and Innovation Amid 2025 Annual Results Release #China #Suzhou #CStone_Pharmaceuticals #CS2009 #Sugemalimab
CStone Secures Historic MHRA Approval for Sugemalimab Treatment in Stage III NSCLC #United_Kingdom #N/A #NSCLC #CStone #Sugemalimab
Sugemalimab Plus Chemotherapy vs Chemotherapy in Gastric Cancer: Cost-Effectiveness Insights from China
oncodaily.com/trial-update...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Sugemalimab #Chemotherapy #GastricCancer #China
CStone Pharmaceuticals Reports 2024 Results and Strategic Developments in Oncology #China #Suzhou #CStone_Pharmaceuticals #Sugemalimab #avapritinib
CStone Pharmaceuticals Advances Sugemalimab Application for Stage III Non-Small Cell Lung Cancer to EMA #China #Suzhou #CStone_Pharmaceuticals #Sugemalimab #Non-Small_Cell_Lung_Cancer
Mit #Sugemalimab wurde jetzt erstmals ein PD-L1-Inhibitor zur Erstlinientherapie von inoperablen lokal fortgeschrittenen oder metastasierten Adenokarzinomen des Magens und des ösophagogastralen Übergangs in einer Phase-3-Studie getestet – mit Erfolg: #Medizin #MedSky #Magenkarzinom
CStone Pharmaceuticals' Sugemalimab Study Breaks Ground in Gastric Cancer Treatment with New JAMA Publication #China #Suzhou #CStone #Sugemalimab #JAMA
CStone Pharmaceuticals Celebrates New ESMO Guideline Inclusion for Sugemalimab Treatment in NSCLC #China #Suzhou #NSCLC #CStone #Sugemalimab
CStone Pharmaceuticals Enters Strategic Partnership with SteinCares for Sugemalimab in Latin America #China #Suzhou #SteinCares #CStone #Sugemalimab